Gastroesophageal Reflux Disease Therapeutics Market Report 2026

Gastroesophageal Reflux Disease Therapeutics Market Overview

• Gastroesophageal Reflux Disease Therapeutics market size has reached to $6.08 billion in 2025 • Expected to grow to $8.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Self-Medication Trends Propel The Gastroesophageal Reflux Disease Therapeutics Market • Market Trend: Advanced Diagnostic Solutions For Gastroesophageal Reflux Disease Therapeutics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastroesophageal Reflux Disease Therapeutics Market?

Gastroesophageal reflux disease (GERD) therapeutics is a medication for chronic medical illness characterized by the upward movement of stomach contents into the esophagus that causes heartburn and regurgitation. The therapeutics are used to neutralize and reduce the production of stomach acid to maintain optimal pH in the gut and prevent the passage of fluids back into the stomach that cause acid reflux. The main gastroesophageal reflux disease therapeutics are branded and generic. Branded refers to any medical substance that may only be supplied according to a prescription order from a physician or other authorized prescriber under state or federal rules and these drugs are used to treatment of gastroesophageal reflux disease to eliminate symptoms and allow esophageal healing. The various drug classes are antacids, proton pump inhibitors, histamine blockers, pro-kinetic agents, and others that are distributed using different channels such as hospital pharmacies, drug stores, general stores, and supermarkets. These are applied in Crohn’s disease, gastroesophageal reflux disease (GERD), and ulcerative colitis.

What Is The Gastroesophageal Reflux Disease Therapeutics Market Growth Forecast?

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $8.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to innovation in drug formulations, expansion of e-pharmacies, adoption of telemedicine for gastro care, increasing investment in precision medicine, growing demand for minimally invasive therapies. Major trends in the forecast period include personalized gerd treatment approaches, development of novel drug delivery systems, rising demand for over-the-counter gerd medications, increased focus on gut health and microbiome regulation, integration of remote patient monitoring and telehealth.

Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation

1) By Type: Branded, Generic 2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class 3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets Subsegments: 1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents 2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents

What Is The Driver Of The Gastroesophageal Reflux Disease Therapeutics Market?

The adoption of self-medication is significantly contributing to the growth of the gastroesophageal reflux disease therapeutics market going forward. Self-medication is the practice of using drugs or other substances to treat a medical condition without consulting a healthcare professional. Self-medication plays a significant role in identifying and avoiding trigger foods, managing stress, and quitting smoking, which can significantly improve GERD symptoms. For instance, in July 2024, the Proprietary Association of Great Britain (PAGB), a UK-based trade association, reported that with 64 million UK residents experiencing at least one self-treatable condition in 2023, the proportion of GP-advised cases directed to over-the-counter self-care rose markedly from 58% in 2023 to 75% in 2024, while consumer confidence in using these medications increased to 89%, reflecting an 8-point gain over the previous year. Therefore, the adoption of self-medication is driving the gastroesophageal reflux disease therapeutics industry.

Key Players In The Global Gastroesophageal Reflux Disease Therapeutics Market

Major companies operating in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

Global Gastroesophageal Reflux Disease Therapeutics Market Trends and Insights

Major companies operating in the gastroesophageal reflux disease therapeutics market are concentrating towards developing innovative systems such as wireless pH-capsule reflux testing systems. Wireless pH-capsule reflux testing systems are medical devices designed for the diagnosis and monitoring of gastroesophageal reflux disease (GERD) and related conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a US-based medical testing equipment manufacturing company, announced the launch of alpHaONE system. It is a wireless pH-capsule reflux testing system that is specifically designed to diagnose gastroesophageal reflux disease (GERD). The system offers up to 96 hours of data monitoring, provides accurate and reliable data. alpHaONE presents a distinctive solution featuring an ergonomic and compact design, enlarged buttons that are easy to press, and a fail-safe capsule delivery system designed to safeguard the patients oesophagus.

What Are Latest Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market?

In July 2024, Merit Medical Systems, a US-based provider of disposable medical devices and interventional, diagnostic, and therapeutic systems, acquired EndoGastric Solutions, Inc. for $105 million. With this acquisition, Merit aims to expand its gastrointestinal endoscopy portfolio by integrating a minimally invasive, non-pharmacological treatment for gastroesophageal reflux disease (GERD), thereby addressing a significant unmet clinical need. EndoGastric Solutions is a US-based medical device company that develops and commercializes the EsophyX Z+ device and related incisionless surgical technology for GERD therapy.

Regional Insights

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastroesophageal Reflux Disease Therapeutics Market?

The gastroesophageal reflux disease (GERD) therapeutics market consists of sales of amino-salicylates (5-ASA), corticosteroids, immunomodulators, antibiotics, biologics, and dopamine receptor antagonist. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastroesophageal Reflux Disease Therapeutics Market Report 2026?

The gastroesophageal reflux disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.